{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=8", "query": { "intervention": "Dose C", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 3877, "total_pages": 388, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T17:06:03.379Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Leukemia, Lymphocytic, Acute", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Enzomenib", "type": "DRUG" }, { "name": "azoles", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Intensive chemotherapy with 7 + 3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 606, "start_date": "2022-02-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 33, "location_summary": "Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04988555" }, { "nct_id": "NCT07656727", "title": "A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity and Cardiovascular Risk" ], "interventions": [ { "name": "Oral BGE-102", "type": "DRUG" }, { "name": "Oral Placebo Matching BGE-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioAge Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-06-11", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 16, "location_summary": "Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07656727" }, { "nct_id": "NCT00723385", "title": "Effects of Vitamin D on Lipids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypercholesterolemia", "Vitamin D Deficiency" ], "interventions": [ { "name": "Vitamin D (1000 or 2000 IU/day)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2008-07", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2015-04-08", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00723385" }, { "nct_id": "NCT06630117", "title": "A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "V330", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 245, "start_date": "2024-03-01", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 4, "location_summary": "Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630117" }, { "nct_id": "NCT04810078", "title": "A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab and rHuPH20", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 681, "start_date": "2021-05-21", "completion_date": "2027-05-10", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 3, "location_summary": "Chicago, Illinois • Buffalo, New York • West Reading, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" }, { "city": "West Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04810078" }, { "nct_id": "NCT05406440", "title": "A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 53, "start_date": "2022-07-12", "completion_date": "2023-02-24", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 3, "location_summary": "Garden Grove, California • Glendale, California • Marlton, New Jersey", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05406440" }, { "nct_id": "NCT00003190", "title": "Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "valspodar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 640, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003190" }, { "nct_id": "NCT04771897", "title": "A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Diffuse Midline Glioma, H3 K27M-Mutant" ], "interventions": [ { "name": "BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance", "type": "DRUG" }, { "name": "BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 10, "start_date": "2021-05-24", "completion_date": "2024-10-04", "has_results": false, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 3, "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771897" }, { "nct_id": "NCT03661034", "title": "Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease, Early Onset", "Alzheimer Disease", "Alzheimer Dementia", "Mild Cognitive Impairment", "Memory Disorders", "Memory Loss", "Memory Impairment", "Memory Disorders, Age Related", "Alzheimer Disease, Late Onset", "Cognitive Impairment", "Dementia, Mild", "Dementia, Alzheimer Type", "Cognitive Decline" ], "interventions": [ { "name": "GammaSense Stimulation System (non-invasive, non-significant risk)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 20, "start_date": "2018-05-31", "completion_date": "2022-03-01", "has_results": false, "last_update_posted_date": "2021-08-24", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 1, "location_summary": "Newton, Massachusetts", "locations": [ { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03661034" }, { "nct_id": "NCT07477704", "title": "A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 438, "start_date": "2026-06-17", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-19T17:06:03.379Z", "location_count": 34, "location_summary": "Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07477704" } ] }